Aminotransferase Levels and 20-Year Risk of Metabolic Syndrome, Diabetes, and Cardiovascular Disease

Gastroenterology

Volumn 135, Issue 6, 2008, Pages

  Goessling, Wolfram ^a,b   Massaro, Joseph M ^d   Vasan, Ramachandran S ^c,f   D'Agostino Sr , Ralph B ^e   Ellison, R Curtis ^f   Fox, Caroline S ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

^d BOSTON UNIVERSITY   (United States)

^e Boston University   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 57349163062     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.09.018     Document Type: Article

References (57)

1. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 (2000) 112-117
2. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
3. Cortez-Pinto H., Camilo M.E., Baptista A., et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr 18 (1999) 353-358
4. Bedogni G., Miglioli L., Masutti F., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42 (2005) 44-52
5. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
6. Nanji A.A., French S.W., and Freeman J.B. Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 36 (1986) 266-269
7. Chang Y., Ryu S., Sung E., and Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem 53 (2007) 686-692
8. Ruhl C.E., and Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124 (2003) 71-79
9. Ioannou G.N., Weiss N.S., Boyko E.J., et al. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 128 (2005) 627-635
10. Hanley A.J., Williams K., Festa A., et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54 (2005) 3140-3147
11. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med 24 (2007) 430-435
12. Targher G., Bertolini L., Padovani R., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30 (2007) 1212-1218
13. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 24 (2007) 1-6
14. Goland S., Shimoni S., Zornitzki T., et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 40 (2006) 949-955
15. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006) 865-873
16. Targher G., Bertolini L., Padovani R., et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest 29 (2006) 55-60
17. Targher G., Bertolini L., Poli F., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54 (2005) 3541-3546
18. Pratt D.S., and Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342 (2000) 1266-1271
19. Zanella A., Conte D., Prati D., et al. Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay. Hepatology 21 (1995) 913-917
20. Prati D., Capelli C., Zanella A., et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 110 (1996) 178-183
21. Alberti A., Morsica G., Chemello L., et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 340 (1992) 697-698
22. Kunde S.S., Lazenby A.J., Clements R.H., and Abrams G.A. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 42 (2005) 650-656
23. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
24. Kim H.C., Nam C.M., Jee S.H., et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 328 (2004) 983
25. Mofrad P., Contos M.J., Haque M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003) 1286-1292
26. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
27. Dawber T.R., Meadors G.F., and Moore Jr. F.E. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health 41 (1951) 279-281
28. Dawber T.R., Kannel W.B., and Lyell L.P. An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci 107 (1963) 539-556
29. Kannel W.B., Feinleib M., McNamara P.M., et al. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 110 (1979) 281-290
30. Becker U., Deis A., Sorensen T.I., et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 23 (1996) 1025-1029
31. Bellentani S., Saccoccio G., Costa G., et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 41 (1997) 845-850
32. Henry R.J., Chiamori N., Golub O.J., and Berkman S. Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase. Am J Clin Pathol 34 (1960) 381-398
33. Cupples L.A. DARB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Study, 30-year follow-up. In: Kannel W.B., and Garrison R.J. (Eds). The Framingham Heart Study: An Epidemiological Investigation of Cardiovascular Disease (1987), Government Printing Office, Washington, DC 87-203 NIH Publication, section 34
34. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
35. Freiberg M.S., Pencina M.J., D'Agostino R.B., et al. BMI vs. waist circumference for identifying vascular risk. Obesity 16 (2008) 463-469
36. Siest G., Schiele F., Galteau M.M., et al. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem 21 (1975) 1077-1087
37. SAS/STAT User's Guide. Version 8 (2000), SAS Institute Inc, Cary, NC
38. Jeong S.K., Nam H.S., Rhee J.A., et al. Metabolic syndrome and ALT: a community study in adult Koreans. Int J Obes Relat Metab Disord 28 (2004) 1033-1038
39. Kim H.C., Choi K.S., Jang Y.H., et al. Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys. Yonsei Med J 47 (2006) 542-550
40. Fraser A., Longnecker M.P., and Lawlor D.A. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 133 (2007) 1814-1820
41. Wannamethee S.G., Shaper A.G., Lennon L., and Whincup P.H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28 (2005) 2913-2918
42. Vozarova B., Stefan N., Lindsay R.S., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 (2002) 1889-1895
43. Hanley A.J., Williams K., Festa A., et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 53 (2004) 2623-2632
44. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191 (2007) 391-396
45. Lee D.S., Evans J.C., Robins S.J., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 27 (2007) 127-133
46. Lee D.H., Blomhoff R., and Jacobs Jr. D.R. Is serum gamma glutamyltransferase a marker of oxidative stress?. Free Radic Res 38 (2004) 535-539
47. Parekh S., and Anania F.A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132 (2007) 2191-2207
48. Pagano C., Soardo G., Esposito W., et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152 (2005) 113-118
49. Nishida M., Funahashi T., and Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol 40 (2007) 55-67
50. Vega G.L., Chandalia M., Szczepaniak L.S., and Grundy S.M. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 46 (2007) 716-722
51. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 (2005) 473-480
52. Mallat A., and Lotersztajn S. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol 294 (2007) G9-G12
53. Lizardi-Cervera J., Chavez-Tapia N.C., Perez-Bautista O., et al. Association among C-reactive protein, fatty liver disease, and cardiovascular risk. Dig Dis Sci 52 (2007) 2375-2379
54. Kew M.C. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 355 (2000) 591-592
55. Green R.M., and Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 123 (2002) 1367-1384
56. Kaplan M.M. Alanine aminotransferase levels: what's normal?. Ann Intern Med 137 (2002) 49-51
57. Ioannou G.N., Boyko E.J., and Lee S.P. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 101 (2006) 76-82